Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.31 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25411825 | 0.85 | PRF1 (0.32) | PRF1MKNK2CA12CA9CDC7 | |
| SCHEMBL30551099 | 0.75 | PARP16 (0.38) | PRF1MKNK2CA12CA9CDC7 | |
| SCHEMBL25323349 | 0.75 | PARP16 (0.38) | PRF1MKNK2CA12CA9CDC7 | |
| SCHEMBL17141532 | 0.75 | PARP10 (0.39) | PRF1MKNK2CA12CA9CDC7 | |
| SCHEMBL12241444 | 0.75 | PARP10 (0.39) | PRF1MKNK2CA12CA9CDC7 | |
| SCHEMBL31310037 | 0.75 | PRF1 (0.41) | PRF1MKNK2CA12CA9CDC7 | |
| SCHEMBL8180707 | 0.71 | HPGD (0.35) | PRF1MKNK2CA12CA9CDC7 | |
| SCHEMBL30099135 | 0.71 | PARP10 (0.43) | PRF1 | |
| SCHEMBL12459133 | 0.71 | PRF1 (0.34) | PRF1MKNK2CA12CA9CDC7 | |
| SCHEMBL30900297 | 0.71 | MKNK2 (0.33) | PRF1MKNK2CA12CA9CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| EP-4490152-A1 | ACTIVATORS OF EFFECTOR T CELLS | Orum Therapeutics Inc. (KR) | 2025-01-15 | — | — | EP | disclosed |
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | PRF1 246/4885MKNK2 3304/4885CA12 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.